Bill Haney, Dragonfly
AbbVie lines up a new preclinical R&D alliance with the dealmakers at natural killer player Dragonfly
Bill Haney is building on his rep as one of the most prolific dealmakers in preclinical R&D, adding a new alliance for Dragonfly Therapeutics with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
